HIPEC treatment tackles cancer that has spread across the lining of the abdomen — a scenario that standard intravenous chemotherapy struggles to reach. In a single operation, surgeons first remove all visible tumour, then bathe the abdominal cavity in heated chemotherapy to destroy the microscopic cancer cells left behind. For carefully selected patients with peritoneal disease, this combined approach has turned a once-untreatable diagnosis into one that can be controlled for years. Here is how it works, what it treats, and how patients can access it through Medical E-Aid.

What is HIPEC?

HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy. It is almost always performed together with cytoreductive surgery (CRS) — the surgical removal of tumour deposits from the peritoneum, the membrane that lines the abdominal cavity and covers its organs. Once the surgeon has removed every visible trace of cancer, a warmed chemotherapy solution (typically heated to around 41–43 °C) is circulated throughout the abdomen for roughly 30 to 90 minutes before being drained. The combination is often referred to as CRS-HIPEC.

The principle is simple but powerful: surgery handles the tumour you can see, and heated chemotherapy handles the cancer cells you cannot.

How HIPEC works

Three ideas make the treatment effective where ordinary chemotherapy falls short:

• Direct delivery: the drug is placed straight into the abdominal cavity, so it reaches the peritoneal surfaces at a far higher concentration than intravenous chemotherapy can — while limiting the dose that circulates through the rest of the body.
• Heat: warming the solution makes many cancer cells more vulnerable to the drug and helps it penetrate tumour tissue more deeply.
• Timing: delivering the chemotherapy in the operating room, immediately after the tumour is removed and before scar tissue forms, allows it to reach every surface evenly.

Because the benefit depends on clearing all visible disease first, complete cytoreduction is the single most important factor in a good outcome. Residual tumour left behind substantially reduces the value of the heated chemotherapy.

What conditions does HIPEC treat?

HIPEC is used for cancers that spread across the peritoneal surface rather than to distant organs, including:

• Pseudomyxoma peritonei and other tumours of appendiceal origin
• Colorectal cancer with peritoneal metastases
• Advanced (stage III) ovarian cancer, at the time of interval surgery
• Peritoneal mesothelioma
• Selected cases of gastric cancer with peritoneal spread
• Primary peritoneal carcinomatosis

Not everyone with abdominal cancer is a candidate. Suitability depends on the type of tumour, how widely it has spread (often scored using the Peritoneal Cancer Index), and whether complete surgical removal is achievable — decisions that require an experienced peritoneal-surface-malignancy team.

Outcomes: what the evidence shows

Results vary by cancer type, tumour biology and how completely the disease can be removed, but published studies from specialised centres are encouraging. In carefully selected patients with isolated peritoneal involvement, specialised centres report a median overall survival of roughly 22 to 63 months and five-year survival between about 19% and 51%.

For advanced ovarian cancer, the landmark Dutch-Belgian OVHIPEC-1 randomised trial, published in the New England Journal of Medicine, found that adding HIPEC to interval cytoreductive surgery extended median overall survival by nearly a year (about 45.7 versus 33.9 months), a benefit that held up at ten-year follow-up.

For pseudomyxoma peritonei of appendiceal origin, long-term results can be striking: with complete cytoreduction and HIPEC, reported ten-year survival has risen well above what repeat debulking surgery alone achieved, and one large multicentre analysis reported a median overall survival measured in years rather than months. Low-grade histology and complete tumour removal are consistently linked to the best outcomes.

The benefits at a glance

• Reaches where IV chemo can’t — high drug concentration delivered directly to peritoneal surfaces
• One coordinated procedure — tumour removal and chemotherapy in a single operation
• Potential for long-term control — durable survival in selected patients, even curative intent for some appendiceal tumours
• Lower whole-body exposure — less of the drug circulates systemically than with intravenous chemotherapy
• An option for peritoneal disease once considered untreatable

What to expect

CRS-HIPEC is a major operation and a significant undertaking. The surgery itself can last many hours, followed by a hospital stay that commonly runs one to two weeks and a recovery period of several weeks at home. As with any complex surgery there are risks, and serious complications occur in a minority of patients, which is why treatment at a high-volume specialist centre matters. Before surgery, the team will assess fitness, imaging and disease extent to confirm that HIPEC is the right choice — and to give a realistic picture of the likely benefit.

Accessing HIPEC with Medical E-Aid

CRS-HIPEC is offered only at specialised surgical-oncology centres with dedicated peritoneal-malignancy programmes. Medical E-Aid connects patients with leading, internationally equipped centres and coordinates the entire journey: an expert medical review of your case, a treatment plan and cost estimate, and full support with travel, visas, interpretation and aftercare. Our AI pre-screening helps match your specific diagnosis to the right specialist and clinic, so you can weigh your options with clarity and confidence.

This article is for general information only and is not medical advice. HIPEC is a major procedure and is suitable only for selected patients; treatment decisions must be made by qualified specialists. Outcome figures are drawn from published clinical studies and may not reflect individual results.

Sources: StatPearls / NCBI Bookshelf (CRS and HIPEC); van Driel et al., OVHIPEC-1 trial, New England Journal of Medicine (2018) and 10-year final analysis; multicentre pseudomyxoma peritonei outcomes, BJS Open (2019); peritoneal carcinomatosis outcomes, PMC.